header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-PUB-161101-6
Identification of novel genes and networks governing hematopoietic stem cell development
Han, T., Yang, C.S., Chang, K.Y., Zhang, D., Imam, F.B., Rana, T.M.
Date: 2016
Source: EMBO reports 17(12): 1814-1828 (Journal)
Registered Authors: Zhang, Danhua
Keywords: RNAi, directed differentiation, embryonic stem cells, hematopoietic stem cells
MeSH Terms:
  • Animals
  • Cell Lineage/genetics
  • Cell Lineage/physiology
  • Cells, Cultured
  • Computational Biology
  • Embryonic Stem Cells/physiology*
  • Fetal Blood/cytology
  • Hematopoiesis*
  • Hematopoietic Stem Cells/physiology*
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Metabolic Networks and Pathways/genetics*
  • Mice
  • RNA Interference
  • Signal Transduction/genetics
  • Zebrafish/genetics
PubMed: 27797851 Full text @ EMBO Rep.
FIGURES
ABSTRACT
Hematopoietic stem cells (HSCs) are capable of giving rise to all blood cell lineages throughout adulthood, and the generation of engraftable HSCs from human pluripotent stem cells is a major goal for regenerative medicine. Here, we describe a functional genome-wide RNAi screen to identify genes required for the differentiation of embryonic stem cell (ESC) into hematopoietic stem/progenitor cells (HSPCs) in vitro We report the discovery of novel genes important for the endothelial-to-hematopoietic transition and subsequently for HSPC specification. High-throughput sequencing and bioinformatic analyses identified twelve groups of genes, including a set of 351 novel genes required for HSPC specification. As in vivo proof of concept, four of these genes, Ap2a1, Mettl22, Lrsam1, and Hal, are selected for validation, confirmed to be essential for HSPC development in zebrafish and for maintenance of human HSCs. Taken together, our results not only identify a number of novel regulatory genes and pathways essential for HSPC development but also serve as valuable resource for directed differentiation of therapy grade HSPCs using human pluripotent stem cells.
ADDITIONAL INFORMATION